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Multiple genetic alterations are well recognized as contributing 
to pancreatic carcinogenesis, although the finding of recurrent copy 
number changes indicates additional targets remain to be found. 
The objective of this study was to identify novel targets of genetic 
alteration that contribute to pancreatic cancer development or 
progression. We used Representational Oligonucleotide Microarray 
Analysis (ROMA) to identify copy number changes in pancreatic 
cancer xenografts, and validated these findings using FISH, quan-
titative PCR, Western blotting and immunohistochemical labeling. 
With this approach, we identified a 0.36-Mb amplification at 
18q11.2 containing two known genes, GATA-6 and cTAGE1. Using 
a cutoff value of 3.0 fold compared to haploid controls, copy number 
gain or amplification was confirmed in 4 of 42 (9.5%) pancreatic 
carcinomas analyzed. Combined genetic and transcriptional anal-
yses showed consistent overexpression of GATA-6 in all carcinomas 
with 18q11.2 gain, as well as in the majority of pancreatic cancers 
examined (17 of 30 cancers, 56.7%) that did not have gain of this 
region. By contrast, overexpression of cTAGE1 was rare in these 
same cancers suggesting GATA-6 is the true target of this copy 
number increase. GATA-6 mRNA overexpression corresponded to 
robust nuclear protein expression in cancer cell lines and resected 
tissues consistent with its role as a transcription factor. Intense 
nuclear labeling was significantly increased in PanIN-3 lesions and 
infiltrating carcinomas compared to normal duct epithelium (p < 
0.000001 and p < 0.003, respectively). Forced overexpression of 
GATA6 in MiaPaca2 cells resulted in increased proliferation and 
growth in soft-agar. Gain and overexpression of the development-
related transcription factor GATA-6 may play an important and 
hitherto unrecognized role in pancreatic carcinogenesis.
Introduction
Multiple genetic alterations are well recognized as contrib-
uting to pancreatic carcinogenesis.1,2 These alterations are largely 
 represented by inactivating mutations or deletions of critical tumor 
suppressor genes, activating mutations in oncogenes, or epigenetic 
modifications. In most instances, the alterations disrupt regulatory 
checkpoints in the cell cycle, the response to DNA damage or cellular 
stress, and signaling pathways related to growth and development. 
However, with the application of global analysis methods to human 
cancers, the finding of recurrent allelic losses or copy number gains 
of specific loci indicates additional genetic targets remain to be 
found.3-7 For example, novel candidate oncogenes include SMURF1 
on 7q21, FGFR1 on 8p12, BIRC2 and BIRC3 on 11q22 and PAK4 
on 19q13 while novel candidate tumor suppressor genes include 
TUSC3 on 8p22 and FEZ1 on 8p23.4-8
The objective of this study was to identify novel targets of genetic 
alteration that contribute to pancreatic cancer development or 
progression. Towards this goal, we used the high resolution method 
Representational Oligonucleotide Microarray Analysis (ROMA) to 
identify novel copy number changes of significance in pancreatic 
cancer.9 A major advantage of ROMA is its high resolution (~4 Mb) 
compared to other copy number technologies due to its ability to 
reduce genomic complexity with a corresponding increase in hybrid-
ization efficiency and signal to noise ratio. With this approach, we 
identified an amplification not recognized by other copy number 
methods on chromosome 18q11.2 that contains only two known 
genes, GATA-6 and cTAGE1, and have confirmed the target of this 
amplification is GATA-6.
Results
Identification of GATA-6 as a target of amplification. 
Representational Oligonucleotide Microarray Analysis (ROMA) 
was used to characterize the copy number alterations in 16 low-pas-
sage pancreatic cancer xenografts from four patients.9,10 Matched 
samples were used to account for the prominent genomic variability 
characteristic of human pancreatic cancers16 and to better identify 
copy number alterations consistently present in all samples from the 
same patient. Despite the prominent genomic instability present 
within each xenograft, consistent deletions and amplifications 
were identified among two or more samples from each individual 
by ROMA (Suppl. Fig. 1). However, no copy number changes 
were identified that were common to any two or more patients’ 
samples. The copy number alterations found are summarized in 
Supplemental Table 1.
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overexpression of GATA-6 mRNA was found in all three cell lines 
relative to the normal diploid cell line HPDE (Fig. 1B). By contrast, 
overexpression of cTAGE1 was detected in only one of these same 
three samples (JD13D) despite its co-amplification with GATA-6, 
and the level of overexpression was less than that for GATA-6 in this 
same cell line. This finding suggested to us that GATA-6 is the poten-
tial gene targeted by this amplification. To confirm that GATA-6 is 
amplified in this cancer we performed FISH using a bacterial arti-
ficial chromosome probe specific to GATA-6 (Fig. 1C). This probe 
revealed a homogeneously staining region, confirming amplification 
of the GATA-6 gene in this cell line and consistent with the findings 
by ROMA and quantitative PCR.
Expression of GATA-6 and cTAGE1 in pancreatic cancer. A 
logical question was whether the amplification of 18q11.2 and 
Review of the copy number changes 
identified by ROMA revealed many 
that were previously reported in human 
pancreatic cancer. These included 
a homozygous deletion of 18q21.1 
that encompassed SMAD4, amplifica-
tion of 8q24 that included c-MYC, 
and a homozygous deletion of 9p21 
that included p16/CDKN2A.6,17,18 
However, a consistent 0.36 Mb ampli-
fication of 18q11.2 was found in all 
three xenografts derived from one 
patient representing the primary carci-
noma (13A Xenograft, 13B Xenograft) 
and a matched lung metastasis (13D 
Xenograft). This amplification was 
predicted to span from 19.6 to 19.9 
Mb on chromosome 18q (chr18: April 
2003 assembly). Examination of the 
RefSeq database in the human genome 
assembly revealed only two genes, 
GATA-6 and cTAGE1/2, were localized 
in this amplified region. Review of 
more recent genome assemblies indi-
cate this region has been re-assigned to 
bps 17,945,134-18,307,805 on chro-
mosome 18, although GATA-6 and 
cTAGE1 remain the only two genes 
assigned to this region.
Identification and validation of 
GATA-6 as a target of amplifica-
tion. To validate this amplification we 
first performed quantitative real-time 
PCR for evaluation of the DNA copy 
number within the 0.36 Mb amplicon 
and normalized these values to flanking 
genomic regions on 18q (primer 
sequences available in Suppl. Table 2). 
Increased DNA copy number for both 
GATA-6 and cTAGE1 was confirmed 
in the three xenografts analyzed by 
ROMA, in microdissected samples of 
the matched original tumor tissues and 
in the low-passage cell lines generated from these xenograft tissues 
but not in the corresponding normal tissue from this patient (Fig. 
1A). Consistently increased DNA copy number for both genes was 
also observed in all other primary and metastatic cancer tissues avail-
able from the same patient (data not shown). The predicted copy 
numbers were higher in both the microdissected tissues and cell 
lines than in the xenograft enriched tissues, most likely due to the 
presence of contaminating mouse DNA. However, the possibility of 
copy number loss with passaging ex vivo might have also contrib-
uted to the lower copy numbers in the cell lines JD13A and JD13D 
compared to their corresponding original tumor tissues.
To gain insight into the gene targeted by this amplification, we 
examined the mRNA levels of these two genes in parallel by quan-
titative real-time PCR in the three low passage cell lines. Consistent 
Figure 1. Expression of GATA-6 and cTAGE1 in cancer samples from patient A13. (A) Copy number analysis 
of the GATA-6 and cTAGE1, the only two genes within the 18q11.2 amplification in the neoplastic tissues, 
xenografts and cell lines of the primary carcinoma and matched lung metastasis from patient A13. All values 
in cancer and normal DNA samples were normalized to that of flanking genomic DNA from within 2–3 Mb 
upstream and downstream of the 18q11.2 amplicon determined from the same template DNA. Increased 
copy number for both genes is evident in both samples of the primary carcinoma (13A and 13B) and lung 
metastasis (13D). (B) Relative mRNA expression of GATA-6 and cTAGE1 in the immortalized normal cell line 
HPDE and in cell lines derived from the primary carcinoma (JD13A, JD13B) and lung metastasis (JD13D) of 
patient 13. All three cells derived from patient A13 show >12-fold overexpression of GATA-6 mRNA relative 
to that of HPDE. By contrast, cTAGE1 expression in the primary cancer cell lines is approximately the same as 
in HPDE, while up to 5-fold overexpression is seen in the metastatic cell line JD13D. (C) Validation of GATA-6 
gene amplification in the cell line JD13A by fluorescent in situ hybridization (FISH) analysis using a probe 
corresponding to GATA-6 located within the minimal amplicon of 18q11.2. The grey arrow highlights the 
homogeneous staining region (HSR) whereas the white arrows indicate single copies of GATA-6.
GATA6 amplification in pancreatic cancer
but without genomic amplification, levels of overexpression often 
exceeded that of the samples with amplification. By contrast, overex-
pression of cTAGE1 was only found in 3 of these 30 cancers samples 
examined (10%), which was significantly lower than the frequency of 
GATA-6 overexpression (p < 0.0001). Surprisingly, two of the three 
cancers with cTAGE1 overexpression were those without genomic 
amplification and with the lowest levels of expression of GATA-6 
(Xenograft 185 and cell line PL8). Taken together, these data lend 
further support to our hypothesis that GATA-6, and not cTAGE1, is 
the target of copy number gain or amplification within the 0.36 Mb 
region identified by ROMA. Given the finding of GATA-6 genomic 
amplification in pancreatic cancer, we next sought to determine if 
GATA-6 is additionally targeted by intragenic mutation. The entire 
coding region of GATA-6 was sequenced in 25 pancreatic cancers but 
no mutations were found.
Characterization of GATA-6 protein expression. To confirm 
that GATA-6 copy number gain and/or mRNA overexpression 
results in translation to protein, we performed Western blotting 
and immunohistochemical labeling using a GATA-6 specific anti-
body raised against an epitope common to both the long and short 
forms of human GATA-6. Shown in Figure 4A, both the long and 
overexpression of GATA-6 were specific for this one carcinoma or 
represents a more general feature of human pancreatic cancers. To 
determine the frequency of GATA-6 copy number gain we screened 
38 pancreatic cancers by quantitative PCR (Fig. 2). GATA-6 copy 
number gain (defined as three or more copies per haploid genome) 
was found in an additional three pancreatic cancers at levels of 
~6 copies (CFPAC1), ~5 copies (Xenograft 235) and ~3 copies 
(Xenograft 200) per haploid genome. When these findings were 
combined with data of the four cancers screened by ROMA, GATA-6 
gain was present in 4 of 42 (9.5%) pancreatic cancers, one of which 
corresponded to a true amplification. We also evaluated DNA copy 
numbers of cTAGE1, which indicated gain in three of these same 
42 cancers (7%), all of which also contained GATA-6 copy number 
gain (Fig. 2).
We next examined the mRNA expression of GATA-6 and cTAGE1 
in 30 of these same pancreatic cancers using quantitative real-time 
PCR. Overexpression of GATA-6 mRNA (>5.0 fold compared 
to normal pancreatic duct cell line HPDE) was demonstrated in 
17 of 30 (56.7%) pancreatic cancers. All three samples with copy 
number gain also showed mRNA overexpression of GATA-6 (Fig. 
3). Moreover, in the 14 cancers with mRNA overexpression >5 fold 
Figure 2. Frequency of copy number gain of GATA-6 and cTAGE1 in pancreatic cancer. Copy number values per haploid genome of GATA-6 and cTAGE1 
in pancreatic cancer cell lines and first passage xenografts were quantified by real-time PCR. The relative cut-off value for copy number gain was set at 
3.0. Using this criterion, 4 of 42 pancreatic cancers showed increased copy number of GATA-6. Three of these same cancers also contained copy number 
gain of cTAGE1.
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or 2, GATA-6 labeling was also present with an equal frequency 
and distribution. However, while labeling of early stage PanINs was 
not significantly different from normal duct epithelium (or from 
each other), a striking difference emerged when comparing normal 
epithelium to samples of PanIN3 (p < 0.000001) (Fig. 5B) or infil-
trating cancer (p < 0.003) (Fig. 5C and D). In these stages of disease, 
GATA-6 nuclear labeling was of greater intensity and was present in 
the majority of cells, often 80% or greater. No difference was found 
in comparing PanIN3 labeling to infiltrating carcinoma, suggesting 
the upregulation of GATA-6 occurs late in carcinogenesis but prior 
to the development of infiltrating carcinoma. Among the infiltrating 
cancers specifically, 133 of 193 cancers (69%) showed an H score 
≥100, and 54 of these (28%) showed an H score ≥200, indicating 
GATA-6 is also overexpressed at a significant frequency in resection 
specimens.
To assess possible functional consequences of GATA-6 overex-
pression in pancreatic cancer, we stably expressed the long form of 
GATA-6 in MiaPaca2, a cell line in which GATA-6 expression was 
absent (Fig. 3), to generate MiaPaca2-hG6. Forced expression of 
GATA-6 in MiaPaca2 was verified by RT-PCR and Western blotting 
(Suppl. Fig. 2). MiaPaca2-hG6 cells exhibited a statistically signifi-
cant increase in cell growth in culture (p < 0.01) and in soft agar 
(p = 0.01) compared with control transfected MiaPaca2 cells 
short forms of GATA-6 are detected in cancer cell lines, although 
increased expression of GATA-6 is generally associated with increased 
amounts of the long form of GATA-6 protein. Protein expression of 
GATA-6 was also highly correlated with mRNA expression levels 
(Fig. 4B). Immunolabeling for GATA-6 revealed that overexpression 
of GATA-6, whether by copy number gain, amplification or mRNA 
overexpression, corresponded to strong nuclear labeling in formalin-
fixed cell pellets created from these same cell lines consistent with the 
known function of GATA-6 as a transcription factor (Fig. 4C).
Immunolabeling for GATA-6 protein expression in pancreatic 
cancer tissues. To determine the frequency of GATA-6 protein 
overexpression in pancreatic cancer tissues, we performed immu-
nolabeling for GATA-6 protein in 14 normal ducts, 8 samples of 
pancreatic intraepithelial neoplasia-1a (PanIN-1a), 13 samples of 
PanIN-1b, 18 samples of PanIN-2, 13 samples of PanIN-3, and 
193 samples of infiltrating pancreatic cancer from resection speci-
mens (Table 1). Immunolabeling was evaluated by calculation of 
the Histology (H) score for each case with H = Intensity (scale 0–3 
with three most positive) x% Positive Cells. GATA-6 labeling was 
detected in the majority of samples of normal duct epithelium, seen 
as scattered cells with positive nuclei (~30% of cells) (Fig. 5A). This 
is consistent with the known role of GATA-6 in differentiation of 
progenitor cells into ductal epithelium.19 Among samples of PanIN1 
Figure 3. Expression of GATA-6 and cTAGE1 in pancreatic cancer. Relative mRNA expression of GATA-6 and cTAGE1 in pancreatic cancer cell lines and 
first passage xenografts using quantitative real-time PCR. All values are normalized to the immortalized normal cell line HPDE for which GATA-6 and cTAGE1 
are both arbitrarily assigned a value of 1.0. Relative values of GATA-6 expression of 5.0 fold or more are seen in 17 of 30 pancreatic cancers analyzed, 
whereas only three of these same cancers showed cTAGE1 overexpression. Arrows indicate those cell lines with copy number gain at 18q11.2.
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and validation of this finding by qPCR, Western Blotting and immu-
nohistochemistry. Using FISH, we also demonstrate that GATA-6 
undergoes true amplification, seen in a homogeneous staining region 
in a cancer cell line. Given the frequency of GATA-6 overexpression 
and copy number gain or amplification, it is curious that GATA-6 
has not been identified in other genomic studies of pancreatic 
cancer. Chromosome copy number studies in pancreatic cancer have 
extensively utilized array-based comparative genomic hybridization 
(aCGH)3-7,20,21 yet almost all of these studies failed to identify the 
18q11.2 amplification even although CFPAC1 cell was included in 
almost all. This may be due to the low resolution sensitivity (0.1 
to 1.0 Mb) of aCGH compared with ROMA (4 Kb), although 
other contributing factors include whether the BAC and/or cDNAs 
utilized in these studies provided coverage of 18q11.2, the local 
clone density, or the filtering criteria in data analysis of each study. 
To our knowledge, the only other study that has identified gain of 
(MiaPaca2-pcDNA3.1) (Fig. 6A and B). To determine if GATA-6 
is oncogenic, we also created stable transfectants of GATA-6 and 
control vectors using the hTERT-immortalized but non-tumorigenic 
normal cell line HPNE. Similar to MiaPaca2-hG6 cells, forced 
GATA-6 expression caused increased growth of HPNE-hG6 in 
vitro (Fig. 6C). However, GATA-6 expression in HPNE did not 
result in increased colony formation in soft-agar nor did it permit 
xenograft formation in nude mice (data not shown). Thus, GATA-6 
may contribute to tumorigenicity of pancreatic cancer but does not 
appear to be oncogenic by itself when overexpressed in association 
with hTERT immortalization.
Discussion
The data presented provide compelling evidence for a role of 
GATA-6 in pancreatic cancer based on our identification of increased 
copy number of this gene by the high-resolution method ROMA, 
Figure 4. Correlation of GATA-6 mRNA and protein expression in pancreatic cancer. (A) Detection of GATA-6 protein in selected pancreatic cancer cells 
by Western blot. Actin levels were also determined on the same blot as a loading control. The mRNA expression of GATA-6 in these same cell lines is 
also shown below the Western blot (B), indicating a good correlation among mRNA and protein expression. (C) Immunohistochemical labeling for GATA-6 
protein in representative pancreatic cancer cell lines with high (JD13A, GM6L, BxPC3, CFPAC1) and low (Capan2, MiaPaca2) expression. Protein 
expression corresponds to nuclear localization of GATA-6. Cytoplasmic labeling is also seen in CFPAC1.
Table 1 Summary of GATA-6 immunolabeling in normal, PanIN and cancer samples
Total samples Normal ducts PanIN1A PanIN1b PanIN2 PanIN3 Infiltrating carcinoma 
 N = 14 N =  8 N = 13 N = 18 N = 13 N = 193
H Score
 Mean ± S.D. 76.8 ± 35.3 71.3 ± 56.7 98.5 ± 48.1 101.1 ± 40.1 114.2 ± 98.5 142.9 ± 85.0
 Number >100 7 (50%) 3 (38%) 10 (77%) 13 (72%) 6 (46%) 133 (69%)
 Number >200 0 0 0 0 5 (38%) 54 (28%)
p values - NS NS NS p < 0.000001a p < 0.003a
aTwo-sided Student’s t-test versus normal duct epithelium.
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response.37,38 In accordance, GATA-6 may represent a key regulator 
of some unrevealed regulatory machinery in pancreatic cancer devel-
opment. As such, GATA-6 provides a new marker for the assessment 
of clinical outcome and as a potential therapeutic intervention for 
human pancreatic cancer.
Methods
Human pancreatic cancer specimens, xenografted tissue and cell 
lines. Xenograft enriched samples of matched primary infiltrating and 
metastatic pancreatic cancer were generated as previously described 
from patients in the Johns Hopkins Gastrointestinal Cancer Rapid 
Medical Donation Program (GICRMDP).10 Additional xenograft 
enriched samples of pancreatic cancer were generously provided by 
Dr. Anirban Maitra at Johns Hopkins Medical Institutions. Fourteen 
established pancreatic cell lines were obtained from the ATCC 
(Manassas VA) and an additional 10 low passage pancreatic cancer 
cell lines were created in our own laboratory.11 All cancer cell lines 
were maintained in DMEM (Invitrogen) supplemented with 10% 
fetal bovine serum. HPDE was maintained in Keratinocyte-SFM 
supplemented with EGF and BPE (Invitrogen) and HPNE was 
cultured in a mixture of M3 Base/DMEM (1:3) (Incell) with 5% fetal 
bovine serum and 10 ng/mL EGF. Samples of paraffin-embedded 
pancreatic cancer tissue from resection specimens were obtained 
from the Department of Surgical Pathology at The Johns Hopkins 
Hospital. The collection and use of all tissue samples for this project 
was approved by the Johns Hopkins Institutional Review Board.
DNA and RNA preparation. Genomic DNA was prepared using 
a DNAeasy Tissue Kit (Qiagen, Valencia CA). DNA was dissolved in 
low TE buffer and stored at -20°C. Total RNA was extracted using 
18q11.2 in pancreatic cancer was reported by 
Heidenblad et al.7 in which a large genomic region 
(~25 Mb) covering 18q11.1-18q12.3 was 
identified. However, that study focused on a 
more prominent region (about 7 Mb) within 
distal 18q12. In addition, since some studies only 
focused on genes within genomic amplifications, 
it is not surprising that GATA-6 overexpression 
was not identified.3,6,8
Despite frequent reports of copy number 
gain, relatively few amplified genes have been 
demonstrated to be involved in pancreatic 
carcinogenesis. These well-characterized genes 
include c-ERBB-2 (27% by FISH), Cyclin D1 
(25% by Southern blot), MYB (10% by Southern 
blot), AKT2 (20% by Southern blot), C-MYC 
(>30% by FISH), AURKA (83% by CGH) and 
AIB1 (66.7% by FISH).22-27 Thus, GATA-6 has 
a relatively low frequency of copy number gain 
(9.5%) in pancreatic cancer. Our findings do 
not rule out the possibility that additional genes 
located qter to GATA-6 are targeted by copy 
number gain or amplification.7 Thus, GATA-6 
gain or amplification may simply reflect variation 
among the spectrum of amplified genes on this 
chromosome as well as the molecular complexity 
of pancreatic cancer. For example, in addition to 
gain and amplification, deletion of 18q11.2 in 
pancreatic cancer has also been described.3
Despite a relative low rate of amplification, GATA-6 is overex-
pressed in the majority of pancreatic cancers analyzed indicating 
that more than one mechanism contributes to its overexpres-
sion. In this respect GATA-6 is quite similar as ERRB2 in which 
elevated expression is frequently observed in pancreatic cancers in 
the absence of gene amplification.28 As gene expression studies of 
pancreatic cancer indicate that numerous genes are deregulated 
during carcinogenesis,29-31 copy number-independent mechanisms 
may play a more important role in gene de-regulation in pancreatic 
cancer. For example, in pancreatic cancers many overexpressed genes 
identified by expression profiling are associated with hypomethyla-
tion.32 Thus, it will be worthwhile to characterize the mechanisms 
underlying GATA-6 upregulation in pancreatic cancer.
At present, it is unclear through which mechanism GATA-6 may 
exert a pro-oncogenic function. GATA-6, together with other five 
zinc-finger transcriptional regulators, is well known for its indis-
pensable role in the development and differentiation of numerous 
endodermal and mesodermal derived organs.19,33 GATA-6 also 
specifically directs pancreatic development by initiating cell type 
specification and differentiation.34 Recent studies, however, have 
revealed that GATA-6 may also contribute oncogenic signals in 
cancer as shown by the ability to induce anomalous dedifferentia-
tion of ovarian tumor cells and to downregulate NSAID-mediated 
15-LOX-1 expression that contributes to the escape of apoptosis in 
colon cancer.35,36 Recently, GATA-6 was shown to participate in 
tissue-specific immune responses in both C. elegans and Drosophila, 
and to protect human lung epithelial cells from infection, suggesting 
post-development GATA-6 is a modulator of the innate immune 
Figure 5. Immunohistochemical labeling for GATA-6 protein. Shown are GATA-6 labeling patterns 
in normal pancreatic duct epithelium (A, 400x), in PanIN 3 (B, 200x), and in two different pan-
creatic cancers (C and D, 400x). Unlike normal epithelium in which scattered positive nuclei are 
seen (indicated by arrows), the higher grade lesions show a marked increase in nuclear labeling 
and intensity.
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representational techniques and thus all oligonucleotides map to BglII 
fragments that are within the representation size range of 200–1000 
bp. The array was originally designed to the June 2002 (NCBI Build 
30) and the coordinates were updated to the April 2003 build for this 
study (NCBI Build 33). They have since been updated to May 2004 
(NCBI Build 35). There are roughly 84,000 features on the array 
and these are scattered across the genome resulting in an average 
resolution of 30 kb. For each sample 2 ug of DNA were labeled and 
hybridized to microarrays and arrays were scanned with an Axon 
GenePix 4000B scanner set at a pixel size of 5 μm. GenePix Pro 4.0 
software was used to quantify the intensity for the arrays. Array data 
were imported into S-PLUS for further analysis. Measured intensi-
ties without background subtraction were used to calculate ratios. 
Data were normalized using an intensity-based lowest curve fitting 
algorithm. Segmentation has been described previously.12 Briefly, the 
ratios are arranged in genome order and are divided into blocks of 
100 data points with arbitrary boundaries, and the boundaries of the 
segments are iteratively moved by minimizing the variance.
Flourescent in situ hybridization (FISH). FISH was performed as 
described in detail by Fox et al.,13 using bacterial artificial chromo-
some clones CTD-2376C8 containing the genomic sequences of the 
18q11.2 amplicon at 0.11 Mb (Invitrogen, Carlsbad, CA).
Quantitative real-time PCR. Quantitative real-time PCR was 
performed to determine genomic DNA copy numbers and gene 
expression levels using protocols recommended by the manufacturer 
(Invitrogen). Primers were specifically designed to exclude cross-
reaction with potential mouse tissue in xenografts and tested for 
performance in quantitative real-time PCR. Only those primer pairs 
showing specific and robust PCR products without detectable primer 
dimers were selected for analysis. PCR reactions were performed 
using an ABI 7300 Real Time PCR system (Applied Biosystems, 
Foster City, CA). For copy number evaluations, primers both within 
the 0.36 amplicon and flanking regions within 2–3 Mb upstream 
and downstream were used. For mRNA expression, the results were 
expressed as the relative fold change (2ΔΔCt) compared to the normal 
cell line HPDE using beta-glucuronidase as an internal control. All 
PCR primers are listed in the Supplemental Table 2.
Western blot analysis. Protein lysates were separated by SDS/
PAGE using 4–12% gels (Invitrogen) and subsequently transferred 
to a 0.45-μm nitrocellulose membrane (Invitrogen). The membrane 
was blocked in wash solution (0.1% Tween 20 in PBS) containing 
5% nonfat dry milk. Rabbit anti-human Gata-6 antibody (Sc-9055 
Santa Cruz Biotechnology) raised against amino acids 358–449 of 
human Gata-6 protein and rabbit TrueBlot (eBioScience) were used 
as the primary and secondary antibodies respectively, followed by 
Lumingen PS-3 as detecting reagent (Amersham). Protein was visual-
ized using a Bio-Rad Quantity One Imaging Device (Bio-Rad).
Immunohistochemistry. Cell pellets and cancer tissues were form-
alin-fixed for 24 hours and embedded in paraffin, and 5 μm sections 
cut from each block. Immunolabeling was performed following stan-
dard methods described in detail in our prior publications14 using 
a 1:50 dilution of primary antibody (rabbit anti-human Gata-6, 
sc-9055, Santa Cruz Biotechnology) and overnight  incubation at 
room temperature. Immunolabeling was detected using the CSA II 
kit (DAKO) following the manufacturers’ protocol and slides were 
counterstained with hematoxylin. A negative control was used in 
each run in which the antibody was replaced by an equal volume 
Figure 6. Oncogenic assays for GATA-6. (A) MiaPaca2 cells were stably 
transfected with control empty (pcDNA3.1, black circle) or GATA-6 expres-
sion vectors (pcDNA3.1-hG6, black triangle) as described in Materials and 
Methods, and proliferative activity determined by MTT assay. A significant 
increase in proliferation is noted in GATA-6 expressing MiaPaca2 cells com-
pared to control transfected cells (p = 0.001, Day four; p = 0.00002, Day 
five, p = 0.0005, Day six). (B) Colony formation in soft agar of control and 
GATA-6 transfected MiaPaca2 cells. A significant increase in colony forma-
tion is noted in GATA-6 expressing MiaPaca2 cells compared to controls 
(p = 0.00009). (C) HPNE cells were stably transfected with the control empty 
vector (pcDNA3.1, black circle) or GATA-6 expression vectors (pcDNA3.1-
hG6, black triangle), and proliferative activity determined by MTT assay. 
Similar to that found for MiaPaca2 cells, a significant increase in prolif-
eration is noted in association with GATA-6 expression (p = 0.0001). All 
values shown represent the mean and standard error of three independent 
experiments.
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RNAeasy Mini Kits (Qiagen), quantified using NanoDrop (NanoDrop 
Technologies, Wilmington, Delaware) and stored at -80°C.
ROMA. Sample preparation, BglII representations, and arrays 
were described in detail previously.9 Briefly, the arrays are based on 
GATA6 amplification in pancreatic cancer
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of phosphate-buffered saline. For resected cancer tissues, immuno-
histochemical labeling was scored on an intensity scale of 0–3, with 
zero corresponding to no labeling of neoplastic epithelial cells, one 
to weak labeling of neoplastic epithelium (labeling best seen at 10X 
objective or greater), two to unequivocal labeling of epithelial cells, 
and three to intense labeling. The percentage of labeled neoplastic 
epithelial cells was scored from zero (complete absence) to 100% (all 
cells labeling). The labeling intensity and labeling percentage were 
used to generate a Histology Score (H-Score) ranging from 0 to 300, 
with H-score = Intensity of immunolabel (range 0 to 3) X percentage 
of reactive cancer cells. H scores of ≥50 were considered positive.
Establishment of stable GATA-6 expression clones. The GATA-6 
expression vector hG6-MALT was generously provided by Dr. 
Clement Ho.15 This vector expresses the long form of human GATA-6 
using the pcDNA3.1 vector (Invitrogen). MiaPaca2 and HPNE cells 
were grown in 6-well plates to 80–90% confluence and transfected 
with empty pcDNA3.1 vector or the pcDNA3.1-hG6 GATA-6 
expression vectors using Lipofectamine 2000 (Invitrogen) following 
the manufacturer’s protocol. Stable expression clones were selected 
with 700 ug/mL geneticin for two weeks and clones were screened by 
RT-PCR and Western blotting using anti-GATA-6 antibody.
Cell proliferation and colony formation assays. Cells (2 x 103) 
were seeded in 96-well plates and the 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyl Tetrazolium Bromide (MTT) assay was performed after 
24, 48, 72 and 96 hours based on the absorbance at 590 nm using an 
ELISA reader 1420 Multilabel Counter (PerkinElmer, Shelton CA). 
For anchorage-independent growth assays, each well of 6-well plates 
was plated with a basal layer of 2 ml of 4% agarose containing 75% 
culture medium. After solidification, 2 ml of 4% agarose containing 
5,000 cells and 87.5% culture medium were added to the wells. Each 
well was finally covered with 1 ml of culture medium with geneticin 
at 250 ug/mL, and the plates were incubated at 37°C. Fourteen days 
after seeding, cells were stained with 0.05% crystal violet (Sigma, St. 
Louis, MO) containing 10% buffered formalin (Sigma) and counted 
using a Bio-Rad Quantity One Imaging Device (Bio-Rad laborato-
ries, Hercules CA). Data were expressed as the mean ± 1 standard 
deviation from triplicates.
Statistical analysis. Statistical significance of data was deter-
mined by using a Student’s t-test for parametric distributions, or a 
Chi-squared test for frequency distributions. p values ≤0.05 were 
considered statistically significant.
Acknowledgements
This work was originally presented at the 2007 American 
Association for Cancer Research 98th Annual Meeting in Los 
Angeles, CA, USA.
Supported by NIH/NCI Specialized Program in Research 
Excellence in Gastrointestinal Pathology CA62924 (C.I.D.), 
CA106610 (C.I.D.) and CA93634 (R.L.), the Department of 
Defense grant W81XWH-05-1-0068 (R.L.), the Lustgarten 
Foundation (R.L.), The Joseph C. Monastra Fund for Pancreatic 
Cancer Research, The Jeff Zgonina Fund for Pancreatic Cancer 
Research, The George Rubis Endowment for Pancreatic Cancer 
Research, The Michael Rolfe Pancreatic Cancer Foundation and 
Sigma Beta Sorority.
Note
Supplementary materials can be found at:
www.landesbioscience.com/supplement/FuCBT7-10-Sup.pdf
1600 Cancer Biology & Therapy 2008; Vol. 7 Issue 10
GATA6 amplification in pancreatic cancer
 23. Wallrapp C, Muller-Pillasch F, Solinas-Toldo S, Lichter P, Friess H, Buchler M, Fink T, 
Adler G, Gress TM. Characterization of a high copy number amplification at 6q24 in 
pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res 1997; 57:3135-9.
 24. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression 
of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol 
Carcinog 1998; 21:81-6.
 25. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. c-MYC activation in primary 
and metastatic ductal adenocarcinoma of the pancreas: Incidence, mechanisms and clinical 
significance. Mod Pathol 2002; 15:462-9.
 26. Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M, Horii A. 
Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic 
adenocarcinoma. Gene Chromosomes Cancer 1997; 19:161-9.
 27. Ghadimi BM, Schrock E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Ried T. Specific 
chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene 
in pancreatic carcinomas. Am J Pathol 1999; 154:525-36.
 28. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are 
implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 2003; 
89:899-906.
 29. Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-Olson JF, Korc M, 
Hammer J, Buchler MW. Microarray-based identification of differentially expressed growth- 
and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003; 60:1180-99.
 30. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, 
Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH. Highly 
expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization 
and comparison of the transcription profiles obtained from three major technologies. 
Cancer Res 2003; 63:8614-22.
 31. Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K, Ishikawa O, 
Ohgaki K, Kashimura N, Miyamoto M, Hirano S, Kondo S, Katoh H, Nakamura Y, 
Katagiri T. Genome-wide cDNA microarray analysis of gene expression profiles in pancre-
atic cancers using populations of tumor cells and normal ductal epithelial cells selected for 
purity by laser microdissection. Oncogene 2004; 23:2385-400.
 32. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, 
Rosty C, Goggins M. Frequent hypomethylation of multiple genes overexpressed in pancre-
atic ductal adenocarcinoma. Cancer Res 2003; 63:4158-66.
 33. Molkentin JD. The zinc finger-containing transcription factors GATA-4, -5 and -6. 
Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 2000; 
275:38949-52.
 34. Ketola I, Otonkoski T, Pulkkinen MA, Niemi H, Palgi J, Jacobsen CM, Wilson DB, 
Heikinheimo M. Transcription factor GATA-6 is expressed in the endocrine and GATA-4 
in the exocrine pancreas. Mol Cell Endocrinol 2004; 226:51-7.
 35. Capo-chichi CD, Roland IH, Vanderveer L, Bao R, Yamagata T, Hirai H, Cohen C, 
Hamilton TC, Godwin AK, Xu XX. Anomalous expression of epithelial differentiation-
determining GATA factors in ovarian tumorigenesis. Cancer Res 2003; 63:4967-77.
 36. Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, Lippman SM. The transcription 
factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in 
human colon cancer. Faseb J 2007; 21:743-53.
 37. Senger K, Harris K, Levine M. GATA factors participate in tissue-specific immune respons-
es in Drosophila larvae. Proc Natl Acad Sci USA 2006; 103:15957-62.
 38. Shapira M, Hamlin BJ, Rong J, Chen K, Ronen M, Tan MW. A conserved role for a GATA 
transcription factor in regulating epithelial innate immune responses. Proc Natl Acad Sci 
USA 2006; 103:14086-91.
www.landesbioscience.com Cancer Biology & Therapy 1601
